Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.49 |
| ▸ | PDE4A | P27815 | 7/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.49 |
| ▸ | ACACB | O00763 | 4/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683038 | 1.00 | PDE4B (0.49) | PDE4BPDE4DPDE4APDE4CACACB | |
| SCHEMBL2136746 | 0.93 | PDE4B (0.49) | PDE4BPDE4DPDE4APDE4CACACB | |
| SCHEMBL682733 | 0.90 | PDE4B (0.47) | PDE4BPDE4DPDE4APDE4CACACB | |
| SCHEMBL681947 | 0.90 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4CACACB | |
| SCHEMBL2137901 | 0.90 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4CACACB | |
| SCHEMBL683078 | 0.88 | PDE4D (0.51) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL874976 | 0.88 | PDE4D (0.51) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL877433 | 0.86 | PDE4B (0.39) | PDE4BPDE4DPDE4APDE4CACACB | |
| SCHEMBL877432 | 0.86 | PDE4B (0.39) | PDE4BPDE4DPDE4APDE4CACACB | |
| SCHEMBL683006 | 0.84 | PDE4B (0.42) | PDE4BPDE4DPDE4APDE4CACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | claimed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | PDE4B 2/4885PDE4D 3/4885PDE4A 1/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | PDE4B 2/4885PDE4D 3/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.